{
    "clinical_study": {
        "@rank": "53804", 
        "arm_group": [
            {
                "arm_group_label": "Aflibercept", 
                "arm_group_type": "Active Comparator", 
                "description": "Blood samples will be collected from patients receiving aflibercept following the first and third dose of standard care therapy."
            }, 
            {
                "arm_group_label": "Bevacizumab", 
                "arm_group_type": "Active Comparator", 
                "description": "Blood samples will be collected from patients receiving bevacizumab following the first and third dose of standard care therapy."
            }, 
            {
                "arm_group_label": "Ranibizumab", 
                "arm_group_type": "Active Comparator", 
                "description": "Blood samples will be collected from patients receiving ranibizumab following the first and third dose of standard care therapy."
            }
        ], 
        "brief_summary": {
            "textblock": "Comparable data for bevacizumab and aflibercept are lacking, as are studies comparing the\n      systemic levels of ranibizumab, bevacizumab, and aflibercept and their relative effects on\n      circulating vascular endothelial growth factor. In the present prospective study, the\n      investigators evaluated serum drug levels and plasma free vascular endothelial growth factor\n      levels in patients with neovascular age-related macular degeneration following intravitreal\n      injections of ranibizumab, bevacizumab and aflibercept."
        }, 
        "brief_title": "Systemic Pharmacokinetics Following Intravitreal Injections of Anti-VEGF", 
        "completion_date": {
            "#text": "April 2014", 
            "@type": "Actual"
        }, 
        "condition": [
            "Age-related Macular Degeneration", 
            "Diabetic Macular Edema", 
            "Retinal Vein Occlusion"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Edema", 
                "Macular Degeneration", 
                "Macular Edema", 
                "Retinal Vein Occlusion", 
                "Wet Macular Degeneration"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Ability to provide written informed consent for participation in this study\n\n          -  Subjects with a diagnosis of neovascular age-related macular degeneration, diabetic\n             macular edema, or reitnal vein occlusion who are either treatment na\u00efve or more than\n             4 months out from a prior intravitreal anti-vascular endothelial growth factor\n             injection\n\n        Exclusion Criteria:\n\n          -  Subjects unwilling to receive 3 monthly injections of anti-vascular endothelial\n             growth factor as initial therapy\n\n          -  Subjects who may need or have received systemic anti-vascular endothelial growth\n             factor for oncology in the past year\n\n          -  Subjects with history of another ocular disease other than neovascular age-related\n             macular degeneration, diabetic macular edema, or reitnal vein occlusion\n\n          -  Subjects with history of vitrectomy"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A"
        }, 
        "enrollment": {
            "#text": "145", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "April 15, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02118831", 
            "org_study_id": "ML28032"
        }, 
        "intervention": [
            {
                "arm_group_label": "Aflibercept", 
                "description": "Subjects will receive intravitreal aflibercept as part of their routine medical care.", 
                "intervention_name": "Aflibercept", 
                "intervention_type": "Drug", 
                "other_name": "Eylea"
            }, 
            {
                "arm_group_label": "Bevacizumab", 
                "description": "Subjects will receive intravitreal bevacizumab as part of their routine medical care.", 
                "intervention_name": "Bevacizumab", 
                "intervention_type": "Drug", 
                "other_name": "Avastin"
            }, 
            {
                "arm_group_label": "Ranibizumab", 
                "description": "Subjects will receive intravitreal ranibizumab injections as part of their routine medical care.", 
                "intervention_name": "Ranibizumab", 
                "intervention_type": "Drug", 
                "other_name": "Lucentis"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Bevacizumab"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "macular degeneration", 
            "diabetic macular edema", 
            "vein occlusion", 
            "vascular endothelial growth factor"
        ], 
        "lastchanged_date": "April 17, 2014", 
        "number_of_arms": "3", 
        "official_title": "Systemic Pharmacokinetics Following Intravitreal Injections of Ranibizumab, Bevacizumab or Aflibercept in Patients With Neovascular Age-related Macular Degeneration", 
        "overall_official": [
            {
                "affiliation": "California Retina Consultants", 
                "last_name": "Robert L Avery, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "California Retina Consultants", 
                "last_name": "Melvin D Rabena, BS", 
                "role": "Study Director"
            }
        ], 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "February 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Serum levels of ranibizumab, bevacizumab or aflibercept will be measured up to 4 months following standard care treatment.", 
            "measure": "Change in Serum Pharmacokinetics Following Treatment", 
            "safety_issue": "No", 
            "time_frame": "Up to 4 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02118831"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Serum and plasma levels of free vascular endothelial growth factor will be measured up to 4 months following treatment.", 
            "measure": "Change in serum and plasma levels of free vascular endothelial growth factor", 
            "safety_issue": "No", 
            "time_frame": "Up to 4 months"
        }, 
        "source": "California Retina Consultants", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "California Retina Consultants", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2012", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}